Clinical Trial Update: Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib) [Phase 3]

View source ↗

Summary

Phase 3 safety study of GSK's DTPa-IPV/Hib vaccine (Infanrix-IPV/Hib) has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Haemophilus Influenzae Type Disease
• Pertussis
• Poliomyelitis
• Tetanus

Drugs mentioned

• Infanrix IPV/Hib (Diphtheria, Tetanus, Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae type b vaccine (DTaP-IPV-Hib))

Snippet

Sponsor: GlaxoSmithKline | Conditions: Haemophilus Influenzae Type b, Acellular Pertussis | Phase 3 | Status: COMPLETED | Results posted: 2017-04-10